Allogene Therapeutics Cuts R&D Spend, Extends Cash Runway to 2029

Allogene Therapeutics reported a second-quarter 2026 loss of 13 cents per share, a result that beat the consensus estimate of a 16-cent loss. The improvement was driven primarily by a substantial reduction in research and development spending, which allowed the company to narrow its deficit compared to the 23-cent loss recorded in the same period a year ago. According to data from GN markets/earnings (en-US), the company generated $4.6 million in collaboration revenues from related parties, marking its first recorded sales revenue as it had zero sales in the prior year period.

The company’s balance sheet was strengthened significantly in the quarter, with total cash, cash equivalents, and investments rising to $423.6 million as of June 30, 2026. This increase from the previous quarter’s $266.9 million was fueled by a public offering completed in April that raised $200.4 million in gross proceeds. Management stated that this liquidity position provides a cash runway extending into 2029, offering a longer-term operational buffer for its clinical programs.

Operating Expenses Shift Toward Administration

Allogene managed its cost structure by cutting R&D expenses to $30.7 million, a 23.5% decrease year over year. This reduction in core scientific spending was offset by a sharp increase in general and administrative expenses, which rose 45.9% to $20.8 million. The shift in spending allocation suggests a focus on corporate infrastructure and overhead management rather than immediate expansion of clinical trials during this period.

Full-Year Guidance Remains Stable

Looking ahead, the company maintained its full-year 2026 operating expense guidance at approximately $225 million. This figure includes non-cash stock-based compensation expenses of nearly $35 million. By holding these estimates steady despite the recent capital raise, Allogene signals that its budgetary planning remains consistent with its previous strategic targets for the remainder of the fiscal year.

Market Reaction Reflects Mixed Signals

Since the last earnings report, Allogene shares have declined 11.1%, underperforming the broader S&P 500 index. Despite this price drop, consensus estimates for the stock have trended upward, with a 22.89% shift in fresh estimates over the past month. The company currently holds a Zacks Rank of #3 (Hold), indicating that analysts expect in-line returns rather than significant outperformance or underperformance in the coming months.